| Name | Title | Contact Details |
|---|---|---|
Mike Sonnenberg |
Vice President | Profile |
Shasta Rizzi |
Associate Director, IT Business Analyst | Profile |
Pionyr Immunotherapeutics discovers and develops first-in-class biologic drugs that fine-tune natural immune responses to increase immune defenses for diseases such as cancer, or to dampen immune responses in autoimmune diseases.
STIMIT`s proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.
HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways.
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.
We are working to methodically engineer durable gene therapies for people with devastating diseases.